November 20th 2024
Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data
View More
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
EnVision Summit
February 14-17, 2025
Register Now!
Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
March 16, 2025
Register Now!
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Acrylic lens is step closer to customized cataract surgery
January 1st 2006Rogers, AR—The recent approval of the Tecnis IOL (AMO) on an acrylic platform gives cataract surgeons another option in an expanding menu of choices, said Randy Cole, MD, FACS, who is medical director and founder of Boozman-Hof Eye Surgery and Laser Center, Rogers, AR.
Read More
Sharp-edged IOL helps prevent PCO, investigators report
January 1st 2006Vienna, Austria—A sharp posterior optic edge design seems to be superior to a double round optic edge design in preventing posterior capsule opacification (PCO). Investigators reported significantly less PCO at 1, 2, and 3 years after implantation of the Sensar OptiEdge AR40e IOL compared with the Sensar AR40 model (both from AMO).
Read More
Monofocal IOL provides optimal spherical aberration compensation
January 1st 2006The development of IOLs has come full circle. In 1949, Sir Harold Ridley attempted to emulate the curvature and size of the natural lens with the development of the Ridley IOL. In subsequent years, the focus was on IOL mechanical issues, materials, and optics. Today, with wavefront technology, researchers are going back to the beginning and are attempting to emulate some of the more subtle features of the natural lens.
Read More
Dislocation, decentration top reasons for IOL explantation
January 1st 2006Lisbon, Portugal—The results of the 7th annual survey on foldable IOLs indicate that dislocation and decentration are the most common reasons for lens explantation, with incorrect lens power the next most important factor.
Read More
Persistent traumatic mydriasis alleviated with cerclage pupilloplasty
December 15th 2005A patient complained of severe glare and light sensitivity associated with a persistent traumatic mydriasis of the right eye. After conservative treatment with topical miotics and a painted contact lens failed to decrease the mydriasis, a cerclage pupilloplasty was performed on the right eye resulting in a 4-mm round pupil. The patient experienced significant reduction of glare and photophobia.
Read More
Learn to maximize profitability at contact lens meeting
December 15th 2005Leading edge programming on contact lenses, solutions, and related eye-care issues is the focal point of the fourth annual Contact Lens and Eyecare Symposium (CLES), Jan. 11 to 15, 2006, at the Royal Pacific Resort at Universal Orlando, FL.
Read More
Persistent traumatic mydriasis alleviated with cerclage pupilloplasty
December 15th 2005A patient complained of severe glare and light sensitivity associated with a persistent traumatic mydriasis of the right eye. After conservative treatment with topical miotics and a painted contact lens failed to decrease the mydriasis, a cerclage pupilloplasty was performed on the right eye resulting in a 4-mm round pupil. The patient experienced significant reduction of glare and photophobia.
Read More
Botulinum toxin considered for multitude of eye problems
October 15th 2005Botulinum toxin type A (Botox, Allergan), originally approved by the FDA as an orphan drug for the treatment of strabismus and blepharospasm, has been found to be effective for the treatment of hemifacial spasm, Meige syndrome, nystagmus, and lid retraction in Graves? disease, according to Matthew Dean Kay, MD, adjunct clinical associate professor, Nova Southeastern University, Pompano Beach, FL.
Read More
Refractive lens exchange surgery increases retinal detachment risk
October 15th 2005Retinal detachment is a significant risk in refractive lens exchange surgery, said Emanuel S. Rosen, MD, at the refractive surgery subspecialty day meeting sponsored by the International Society of Refractive Surgery of the American Academy of Ophthalmology.
Read More
SLT safer than ALT for open-angle glaucoma
October 15th 2005Reading, MA—Selective laser trabeculoplasty (SLT) is safer than argon laser trabeculoplasty (ALT) as a treatment for primary open-angle glaucoma (POAG) and offers the considerable advantage of not causing structural damage to the trabecular meshwork, said Mark A. Latina, MD.
Read More
Will tilt, decentration affect wavefront-corrected IOL result?
October 15th 2005Doubts and concerns regarding efficacy and safety often accompany the introduction of technologies in IOLs. Recent concerns with a wavefront-corrected IOL (Tecnis, Advanced Medical Optics [AMO]) with regard to tilt and decentration are no exception to this rule.
Read More
Luscombe joins Aussie laser manufacturer
October 15th 2005Adelaide, Australia—Ophthalmic laser manufacturer Laserex has appointed Simon Luscombe as vice president of sales, Asia, in an effort to increase its Asian market share. Luscombe previously was in product management and sales management positions at Alcon and Advanced Medical Optics.
Read More
EDTA chelation provides solution for band keratopathy
October 15th 2005Baltimore—Ethylene diamine tetra-acetic acid (EDTA) chelation offers a low-tech, low-cost, effective treatment for calcific band keratopathy associated with chronic uveitis and other disorders, said James P. Dunn, MD, at the Current Concepts in Ophthalmology meeting, sponsored by Johns Hopkins University School of Medicine and Ophthalmology Times.
Read More
Accommodating IOL offers new square-edge design delivered with new injector system
October 14th 2005Eyeonics has developed the crystalens SE System (Square Edge System), a modified design of the original crystalens accommodating IOL, which offers a 360? square-edge optic to help prevent posterior capsule opacification (PCO).
Read More
Modified prolate IOL good choice for piggybacking
October 1st 2005Edina, MN—When IOL piggybacking is needed, combining the modified prolate anterior surface IOL (Tecnis, AMO) with a conventional spherical IOL is a good option because it provides patients the added benefit of improved optical performance and better quality of vision, said Y. Ralph Chu, MD.
Read More
Modified prolate IOL good choice for piggybacking
October 1st 2005Edina, MN—When IOL piggybacking is needed, combining the modified prolate anterior surface IOL (Tecnis, AMO) with a conventional spherical IOL is a good option because it provides patients the added benefit of improved optical performance and better quality of vision, said Y. Ralph Chu, MD.
Read More
Experts highlight latest advances, care at Glaucoma 2005
September 19th 2005San Francisco - A panel of glaucoma experts from across the United States highlighted the latest advances in understanding glaucoma and caring for these patients at “Glaucoma 2005: Mastering Tools and Techniques for the 21st Century,” on Saturday, Sept. 17, at the Ritz-Carlton San Francisco. Now in its 5th year, the program included lectures, panel discussions, and a mini-symposium covering a variety of glaucoma issues with a distinguished faculty.
Read More